💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Voxilaprevir

CHEMBL3707372 Phase 4 Одобрено Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
868.9 g/mol
LogP
5.9
Phase
4

Voxilaprevir is a pan-genotypic nonstructural protein 3/4A (NS3/4A) protease inhibitor that blocks HCV protease-mediated cleavage of the viral polyprotein, preventing replication of all major hepatitis C virus genotypes. It is used in combination with sofosbuvir and velpatasvir (Vosevi) for treatment of HCV infection across genotypes 1-6, particularly in patients who have failed prior DAA therapy. Its pan-genotypic protease inhibition activity complements NS5A and NS5B inhibitors for complete HCV lifecycle blockade.

Молекулярная масса

868,9000 g/mol

LogP

5,90

TPSA

204,00 Ų

Правило пяти Липинского

Не соответствует

Терапевтические области

Cardiovascular Disease Non-Alcoholic Fatty Liver Disease HIV/AIDS Hepatitis C

Механизм действия

Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Механизм

Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.

2D Структура

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC[C@@H]1[C@@H]2CN(C(=O)[C@H](C(C)(C)C)NC(=O)O[C@@H]3C[C@H]3CCCCC(F)(F)c3nc4ccc(OC)cc4nc3O2)[C@@H]1C(=O)N[C@]1(C(=O)NS(=O)(=O)C2(C)CC2)C[C@H]1C(C)C

                

                

                
                

                    
InChI

                    
InChI=1S/C42H58F2N6O9S/c1-9-25-30-21-50(31(25)34(51)48-41(20-26(41)22(2)3)37(53)49-60(55,56)40(7)16-17-40)36(52)33(39(4,5)6)47-38(54)59-29-18-23(29)12-10-11-15-42(43,44)32-35(58-30)46-28-19-24(57-8)13-14-27(28)45-32/h13-14,19,22-23,25-26,29-31,33H,9-12,15-18,20-21H2,1-8H3,(H,47,54)(H,48,51)(H,49,53)/t23-,25-,26+,29-,30+,31+,33-,41-/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C40H52F4N6O9S

                    

                    
                    

                        
HBD / HBA

                        
3 / 15

                    

                    
                    

                        
Вращаемые Связи

                        
9

                    

                    
                    
                    

                        
Тяжёлые Атомы

                        
60

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Часто задаваемые вопросы

                

                    
                    

                        
                        

                            
Voxilaprevir is a pan-genotypic nonstructural protein 3/4A (NS3/4A) protease inhibitor that blocks HCV protease-mediated cleavage of the viral polyprotein, preventing replication of all major hepatitis C virus genotypes. It is used in combination with sofosbuvir and velpatasvir (Vosevi) for treatment of HCV infection across genotypes 1-6, particularly in patients who have failed prior DAA therapy. Its pan-genotypic protease inhibition activity complements NS5A and NS5B inhibitors for complete HCV lifecycle blockade.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits viral protease, an enzyme essential for cleaving polyprotein precursors into functional viral proteins required for viral maturation and infectivity.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Voxilaprevir is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL3707372.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 89921642.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Медицинский отказ от ответственности

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.